Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection
Open Access
- 23 May 2013
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 234
Abstract
Infection with hepatitis C virus (HCV) is associated with high morbidity and increased mortality but many patients avoid initiation of treatment or report challenges with treatment completion. The study objective was to identify motivators and barriers for treatment initiation and completion in a community sample of HCV-infected patients in the United States. Survey methods were employed to identify factors reported by patients as important in their decision to start or complete HCV treatment. Study participants included 120 HCV-infected individuals: 30 had previously completed treatment with pegylated interferon/ribavirin (PR), 30 had discontinued PR, 30 were treated with PR at the time of the survey, and 30 were treatment‒naïve. Telephone interviews occurred between May and August of 2011 and employed a standardized guide. Participants assigned factors a rating from 1 (not at all important) to 5 (extremely important). Trained researchers coded and analyzed interview transcripts. Of 33 factors, expected health problems from not treating HCV infection was reported as most encouraging for treatment initiation and completion, while treatment side effects was most discouraging. Sixty-nine percent of participants reported that the ability to obtain information during treatment on the likelihood of treatment success (i.e., results of viral load testing) would motivate them to initiate therapy. Median preferred timing for learning about test results was 5 weeks (range: 1–23 weeks). Understanding challenges and expectations from patients is important in identifying opportunities for education to optimize patient adherence to their HCV treatment regimen.Keywords
This publication has 20 references indexed in Scilit:
- A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C TreatmentAmerican Journal of Gastroenterology, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Hepatitis C virus infection in USA: an estimate of true prevalenceLiver International, 2011
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Adherence to Hepatitis C Virus Therapy and Early Virologic OutcomesClinical Infectious Diseases, 2009
- Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapySociology of Health & Illness, 2008
- Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.International Journal of Drug Policy, 2008
- Barriers associated with the treatment of hepatitis C virus infection among illicit drug usersDrug and Alcohol Dependence, 2008
- Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do They Alter Their Decision with Time?Digestive Diseases and Sciences, 2007
- Hepatitis Support GroupsGastroenterology Nursing, 2004